Mariagrazia Pizza

Mariagrazia Pizza's AcademicInfluence.com Rankings

Mariagrazia Pizza

Chemistry

#5091

World Rank

#6207

Historical Rank

Organic Chemistry

#865

World Rank

#968

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Mariagrazia Pizza's Degrees

Bachelors Pharmaceutical Chemistry University of Milan
Masters Pharmaceutical Chemistry University of Milan

Why Is Mariagrazia Pizza Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Mariagrazia Pizza is an Italian vaccine researcher who is a professor at Imperial College London. She worked as Senior Scientific Director for Bacterial Vaccines at GSK plc. She was involved with the development of the first pertussis vaccine. In 2023, she was awarded the IVI-SK bioscience Park MahnHoon Award.

(See a Problem?)

Mariagrazia Pizza's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. (2000) (1284)
Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. (2000) (1150)
A universal vaccine for serogroup B meningococcus. (2006) (723)
Reverse vaccinology. (2003) (490)
Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870 (2003) (439)
NadA, a Novel Vaccine Candidate of Neisseria meningitidis (2002) (373)
Mutants of pertussis toxin suitable for vaccine development. (1989) (324)
Reverse vaccinology: a genome-based approach for vaccine development (2002) (316)
Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. (2001) (313)
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines (2010) (306)
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. (2013) (298)
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. (1995) (296)
Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity (1998) (296)
The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells1 (2008) (292)
Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. (1999) (289)
Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells (2004) (248)
Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli (2010) (244)
Reverse vaccinology: a genome-based approach for vaccine development. (2001) (231)
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans (2010) (226)
Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant (1996) (225)
Vaccines, new opportunities for a new society (2014) (223)
Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination (2011) (209)
CD81 Is a Central Regulator of Cellular Events Required for Hepatitis C Virus Infection of Human Hepatocytes (2008) (206)
Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection (1997) (189)
Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin (1997) (184)
Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. (1998) (182)
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88 (2011) (168)
KDEL Receptor (Erd2p)-mediated Retrograde Transport of the Cholera Toxin A Subunit from the Golgi Involves COPI, p23, and the COOH Terminus of Erd2p (1998) (167)
A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. (2000) (158)
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells (2009) (153)
Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis (2017) (146)
Transcriptome Analysis of Neisseria meningitidis in Human Whole Blood and Mutagenesis Studies Identify Virulence Factors Involved in Blood Survival (2011) (146)
NadA Diversity and Carriage in Neisseria meningitidis (2004) (143)
Outer membrane vesicles from group B Neisseria meningitidis Δgna33 mutant: Proteomic and immunological comparison with detergent‐derived outer membrane vesicles (2006) (143)
Rational Design of a Meningococcal Antigen Inducing Broad Protective Immunity (2011) (141)
Proteomics Characterization of Outer Membrane Vesicles from the Extraintestinal Pathogenic Escherichia coli ΔtolR IHE3034 Mutant*S (2008) (136)
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. (2013) (134)
Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. (2009) (132)
Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. (2004) (131)
Two years into reverse vaccinology. (2003) (126)
Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen (2013) (124)
Factor H-Binding Protein Is Important for Meningococcal Survival in Human Whole Blood and Serum and in the Presence of the Antimicrobial Peptide LL-37 (2008) (121)
A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit (1994) (117)
Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough (1990) (115)
A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins (1995) (113)
Probing the structure‐activity relationship of Escherichia coli LT‐A by site‐directed mutagenesis (1994) (113)
Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines (2003) (111)
Neisseria meningitidis NhhA is a multifunctional trimeric autotransporter adhesin (2006) (110)
Common features of the NAD‐binding and catalytic site of ADP‐ribosylating toxins (1994) (109)
Neisseria meningitidis App, a new adhesin with autocatalytic serine protease activity (2003) (108)
Neisseria meningitidis: pathogenesis and immunity. (2015) (108)
Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. (2011) (108)
Ng‐MIP, a surface‐exposed lipoprotein of Neisseria gonorrhoeae, has a peptidyl‐prolyl cis/trans isomerase (PPIase) activity and is involved in persistence in macrophages (2005) (107)
Characterization of fHbp, nhba (gna2132), nadA, porA, and Sequence Type in Group B Meningococcal Case Isolates Collected in England and Wales during January 2008 and Potential Coverage of an Investigational Group B Meningococcal Vaccine (2010) (107)
Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells (1999) (105)
Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? (2013) (104)
MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. (1999) (103)
Escherichia coli Heat-Labile Enterotoxin Promotes Protective Th17 Responses against Infection by Driving Innate IL-1 and IL-23 Production (2011) (103)
Subunit S1 of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity. (1988) (101)
Protective Levels of Diphtheria-Neutralizing Antibody Induced in Healthy Volunteers by Unilateral Priming-Boosting Intranasal Immunization Associated with Restricted Ipsilateral Mucosal Secretory Immunoglobulin A (2003) (100)
The Region Comprising Amino Acids 100 to 255 of Neisseria meningitidis Lipoprotein GNA 1870 Elicits Bactericidal Antibodies (2005) (99)
Intimin-Specific Immune Responses Prevent Bacterial Colonization by the Attaching-Effacing PathogenCitrobacter rodentium (2001) (99)
The impact of genomics on vaccine design. (2005) (98)
Modulation of Innate and Acquired Immune Responses by Escherichia coli Heat-Labile Toxin: Distinct Pro- and Anti-Inflammatory Effects of the Nontoxic AB Complex and the Enzyme Activity1 (2000) (98)
Genome sequencing of disease and carriage isolates of nontypeable Haemophilus influenzae identifies discrete population structure (2014) (96)
Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. (2010) (96)
Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England (2016) (95)
Dual RNA-seq of Nontypeable Haemophilus influenzae and Host Cell Transcriptomes Reveals Novel Insights into Host-Pathogen Cross Talk (2015) (91)
Genetically Detoxified Mutants of Heat-Labile Toxin from Escherichia coli Are Able To Act as Oral Adjuvants (1999) (91)
FdeC, a Novel Broadly Conserved Escherichia coli Adhesin Eliciting Protection against Urinary Tract Infections (2012) (87)
Characterization of fHbp, nhba (gna2132), nadA, porA, Sequence Type (ST), and Genomic Presence of IS1301 in Group B Meningococcal ST269 Clonal Complex Isolates from England and Wales (2009) (86)
Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit (1995) (81)
Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. (1998) (79)
Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. (2004) (77)
Genome-based approaches to develop vaccines against bacterial pathogens. (2009) (76)
The genome revolution in vaccine research. (2004) (73)
Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability To Bind fH, To Mediate Serum Resistance, and To Induce Bactericidal Antibodies (2010) (71)
Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined (2016) (70)
Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908 (1996) (68)
Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. (2004) (68)
Meningococcal protein antigens and vaccines. (2009) (67)
The adjuvant effect of a non‐toxic mutant of heat‐labile enterotoxin of Escherichia coli for the induction of measles virus‐specific CTL responses after intranasal co‐immunization with a synthetic peptide (1996) (66)
Interlaboratory Standardization of the Sandwich Enzyme-Linked Immunosorbent Assay Designed for MATS, a Rapid, Reproducible Method for Estimating the Strain Coverage of Investigational Vaccines (2012) (65)
Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development (2018) (64)
The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology (2019) (64)
Solution Structure of the Factor H-binding Protein, a Survival Factor and Protective Antigen of Neisseria meningitidis* (2009) (63)
Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens. (2004) (63)
Intranasal Immunization with Pneumococcal Polysaccharide Conjugate Vaccines with Nontoxic Mutants of Escherichia coliHeat-Labile Enterotoxins as Adjuvants Protects Mice against Invasive Pneumococcal Infections (1999) (63)
Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody (2014) (61)
Mapping of a Protective Epitope of Pertussis Toxin by In Vitro Refolding of Recombinant Fragments (1988) (61)
Conservation of Meningococcal Antigens in the Genus Neisseria (2013) (60)
Attenuated Shigella flexneri 2a Vaccine Strain CVD 1204 Expressing Colonization Factor Antigen I and Mutant Heat-Labile Enterotoxin of Enterotoxigenic Escherichia coli (2000) (58)
GNA33 of Neisseria meningitidis Is a Lipoprotein Required for Cell Separation, Membrane Architecture, and Virulence (2004) (58)
Identification of Neisseria meningitidis Nonlipopolysaccharide Ligands for Class A Macrophage Scavenger Receptor by Using a Novel Assay (2006) (57)
Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment. (2017) (57)
The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. (1999) (55)
Neisseria Adhesin A Variation and Revised Nomenclature Scheme (2014) (54)
Vaccines against Meningococcal Diseases (2020) (54)
Emerging experience with meningococcal serogroup B protein vaccines (2017) (52)
Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis. (2009) (52)
SslE Elicits Functional Antibodies That Impair In Vitro Mucinase Activity and In Vivo Colonization by Both Intestinal and Extraintestinal Escherichia coli Strains (2014) (52)
Transcriptional Regulation of the nadA Gene in Neisseria meningitidis Impacts the Prediction of Coverage of a Multicomponent Meningococcal Serogroup B Vaccine (2012) (51)
Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. (2011) (51)
Meningococcal B vaccine (4CMenB): the journey from research to real world experience (2018) (50)
Identification of a new OmpA‐like protein in Neisseria gonorrhoeae involved in the binding to human epithelial cells and in vivo colonization (2007) (50)
Properties of the B oligomer of pertussis toxin (1991) (50)
Pathogenic E. coli Exploits SslE Mucinase Activity to Translocate through the Mucosal Barrier and Get Access to Host Cells (2015) (50)
Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop (1997) (48)
Vaccines Against Antimicrobial Resistance (2020) (48)
RrgB321, a Fusion Protein of the Three Variants of the Pneumococcal Pilus Backbone RrgB, Is Protective In Vivo and Elicits Opsonic Antibodies (2011) (46)
An Analysis of the Sequence Variability of Meningococcal fHbp, NadA and NHBA over a 50-Year Period in the Netherlands (2013) (46)
NarE: a novel ADP‐ribosyltransferase from Neisseria meningitidis (2003) (46)
The Two Variants of the Streptococcus pneumoniae Pilus 1 RrgA Adhesin Retain the Same Function and Elicit Cross-Protection In Vivo (2010) (45)
The subunit S1 is important for pertussis toxin secretion. (1990) (45)
Solution Structure of the Immunodominant Domain of Protective Antigen GNA1870 of Neisseria meningitidis* (2006) (45)
Introduction of Zwitterionic Motifs into Bacterial Polysaccharides Generates TLR2 Agonists Able to Activate APCs (2007) (44)
Protective Efficacy Induced by Recombinant Clostridium difficile Toxin Fragments (2013) (44)
Vaccinology in the post−COVID-19 era (2021) (44)
HadA is an atypical new multifunctional trimeric coiled‐coil adhesin of Haemophilus influenzae biogroup aegyptius, which promotes entry into host cells (2009) (44)
SR-A, MARCO and TLRs Differentially Recognise Selected Surface Proteins from Neisseria meningitidis: an Example of Fine Specificity in Microbial Ligand Recognition by Innate Immune Receptors (2008) (43)
Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes (2018) (41)
Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin (1996) (40)
Molecular and Serological Diversity of Neisseria meningitidis Carrier Strains Isolated from Italian Students Aged 14 to 22 Years (2014) (40)
Structure of the C-terminal Domain of Neisseria Heparin Binding Antigen (NHBA), One of the Main Antigens of a Novel Vaccine against Neisseria meningitidis* (2011) (40)
Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. (2010) (39)
Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines (2014) (38)
Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. (2017) (37)
Two cross‐reactive monoclonal antibodies recognize overlapping epitopes on Neisseria meningitidis factor H binding protein but have different functional properties (2014) (36)
Novel meningococcal 4CMenB vaccine antigens – prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae (2012) (35)
Neisserial Heparin Binding Antigen (NHBA) Contributes to the Adhesion of Neisseria meningitidis to Human Epithelial Cells (2016) (35)
Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults (2011) (35)
Escherichia coli: Great Diversity around a Common Core (2012) (35)
LytM Proteins Play a Crucial Role in Cell Separation, Outer Membrane Composition, and Pathogenesis in Nontypeable Haemophilus influenzae (2015) (34)
A Recombinant Live Attenuated Strain of Vibrio cholerae Induces Immunity against Tetanus Toxin andBordetella pertussis Tracheal Colonization Factor (1998) (34)
Factor H-binding protein, a unique meningococcal vaccine antigen. (2008) (33)
Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. (2003) (33)
The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization. (1996) (33)
Identification of errors among database sequence entries and comparison of correct amino acid sequences for the heat‐labile enterotoxins of Escherichia coli and Vibrio cholerae (1995) (33)
Human heat shock protein (Hsp) 90 interferes with Neisseria meningitidis adhesin A (NadA)‐mediated adhesion and invasion (2012) (33)
Progress towards the development of new vaccines against whooping cough. (1992) (32)
MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine (2012) (32)
Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. (2003) (32)
In silico identification of novel bacterial ADP-ribosyltransferases. (2004) (31)
Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides. (1999) (31)
Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment. (1995) (29)
Genetic detoxification of bacterial toxins: a new approach to vaccine development. (1995) (29)
Recognition of Neisseria meningitidis by the Long Pentraxin PTX3 and Its Role as an Endogenous Adjuvant (2015) (28)
Outer Membrane Vesicles (OMV)-based and Proteomics-driven Antigen Selection Identifies Novel Factors Contributing to Bordetella pertussis Adhesion to Epithelial Cells* (2017) (28)
Molecular Determinants of Surface Colonisation in Diarrhoeagenic Escherichia coli (DEC): from Bacterial Adhesion to Biofilm Formation. (2020) (27)
Mutation of a buried residue causes loss of activity but no conformational change in the heat-labile enterotoxin of Escherichia coli (1995) (27)
The Arg7Lys mutant of heat-labile enterotoxin exhibits great flexibility of active site loop 47-56 of the A subunit. (1995) (27)
Vaccines Against Escherichia coli. (2018) (26)
Crystal structure of a non‐toxic mutant of heat‐labile enterotoxin, which is a potent mucosal adjuvant (1997) (25)
Mucosal delivery of vaccines. (1999) (24)
LTK63 and LTR72, two mucosal adjuvants ready for clinical trials. (2000) (24)
Acellular pertussis vaccine composed of genetically inactivated pertussis toxin. (1995) (23)
Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. (2020) (23)
The C2 fragment from Neisseria meningitidis antigen NHBA increases endothelial permeability by destabilizing adherens junctions (2014) (23)
Neisseria meningitidis subverts the polarized organization and intracellular trafficking of host cells to cross the epithelial barrier (2015) (22)
IEM101, a naturally attenuated Vibrio cholerae strain as carrier for genetically detoxified derivatives of cholera toxin. (2000) (22)
Toward a Meningitis-Free World (2012) (21)
Towards third-generation whooping cough vaccines. (1991) (21)
EsiB, a Novel Pathogenic Escherichia coli Secretory Immunoglobulin A-Binding Protein Impairing Neutrophil Activation (2013) (21)
The factor H binding protein of Neisseria meningitidis interacts with xenosiderophores in vitro. (2012) (21)
Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence. (2020) (21)
Molecular Basis of Ligand-Dependent Regulation of NadR, the Transcriptional Repressor of Meningococcal Virulence Factor NadA (2016) (21)
Effects of Site-Directed Mutagenesis ofEscherichia coli Heat-Labile Enterotoxin on ADP-Ribosyltransferase Activity and Interaction with ADP-Ribosylation Factors (1999) (20)
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal (2017) (20)
A Large Portion of Meningococcal Antigen Typing System-Negative Meningococcal Strains from Spain Is Killed by Sera from Adolescents and Infants Immunized with 4CMenB (2015) (20)
Molecular basis of vaccination. (1998) (19)
Exploring host-pathogen interactions through genome wide protein microarray analysis (2016) (19)
Antigen identification starting from the genome: a "Reverse Vaccinology" approach applied to MenB. (2012) (19)
Structural and Biochemical Characterization of NarE, an Iron-containing ADP-ribosyltransferase from Neisseria meningitidis* (2011) (19)
Diversity of cwp loci in clinical isolates of Clostridium difficile. (2013) (18)
Role of ARF6, Rab11 and External Hsp90 in the Trafficking and Recycling of Recombinant-Soluble Neisseria meningitidis Adhesin A (rNadA) in Human Epithelial Cells (2014) (18)
Adjuvant effect of non-toxic mutants of E. coli heat-labile enterotoxin following intranasal, oral and intravaginal immunization. (1998) (18)
Physiopathological roles of spontaneously released outer membrane vesicles of Bordetella pertussis. (2017) (17)
Identification of the Autochaperone Domain in the Type Va Secretion System (T5aSS): Prevalent Feature of Autotransporters with a β-Helical Passenger (2018) (16)
Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule (1992) (16)
The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A. (2015) (16)
CHAPTER 12 – Molecular, functional, and evolutionary aspects of ADP-ribosylating toxins (2006) (16)
Crystal structure reveals vaccine elicited bactericidal human antibody targeting a conserved epitope on meningococcal fHbp (2018) (16)
NadA3 Structures Reveal Undecad Coiled Coils and LOX1 Binding Regions Competed by Meningococcus B Vaccine-Elicited Human Antibodies (2018) (15)
Vaccines to Overcome Antibiotic Resistance: The Challenge of Burkholderia cenocepacia. (2020) (14)
GMMA-Based Vaccines: The Known and The Unknown (2021) (13)
Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination: Real-world effectiveness of MenB vaccination. (2021) (13)
Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response. (1992) (13)
4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents (2020) (13)
Exploiting chimeric human antibodies to characterize a protective epitope of Neisseria adhesin A, one of the Bexsero vaccine components (2016) (12)
Common Features of ADP—Ribosyltransferases (2000) (12)
Differential biotin labelling of the cell envelope proteins in lipopolysaccharidic diderm bacteria: Exploring the proteosurfaceome of Escherichia coli using sulfo-NHS-SS-biotin and sulfo-NHS-PEG4-bismannose-SS-biotin. (2018) (12)
Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules (2019) (12)
Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway. (2014) (11)
A Naturally Occurring Single-Residue Mutation in the Translocator Domain of Neisseria meningitidis NhhA Affects Trimerization, Surface Localization, and Adhesive Capabilities (2011) (11)
Molecular analysis of two novel Neisseria gonorrhoeae virulent components: the macrophage infectivity potentiator and the outer membrane protein A. (2010) (11)
Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin. (1992) (11)
Mixed mucosal-parenteral immunizations with the broadly conserved pathogenic Escherichia coli antigen SslE induce a robust mucosal and systemic immunity without affecting the murine intestinal microbiota. (2019) (10)
Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect (2021) (10)
Interaction of Klebsiella pneumoniae with tissue macrophages in a mouse infection model and ex-vivo pig organ perfusions: an exploratory investigation (2021) (10)
New vaccines against bacterial toxins. (1996) (10)
Meningococcus B: From Genome to Vaccine (2005) (9)
Auto ADP‐ribosylation of NarE, a Neisseria meningitidis ADP‐ribosyltransferase, regulates its catalytic activities (2013) (9)
Antigens from Neisseria meningitidis (1999) (9)
A combined approach to assess the potential coverage of a multicomponent protein-based vaccine. (2012) (9)
Development of a serological assay to predict antibody bactericidal activity against non-typeable Haemophilus influenzae (2015) (9)
Identification of an Iron-Sulfur Cluster That Modulates the Enzymatic Activity in NarE, a Neisseria meningitidis ADP-ribosyltransferase* (2009) (9)
Biochemical and biological activities of recombinant S1 subunit of pertussis toxin (1990) (9)
Advances in meningococcal vaccines (2012) (9)
Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity (2020) (9)
Mutant pertussis and Escherichia coli heat-labile toxins as adjuvants for enhancing local and systemic immune responses to coadministered, nonliving antigens (1997) (9)
Meningococcal factor H-binding protein as immune evasion factor and vaccine antigen. (2020) (9)
A novel high-throughput assay to quantify the vaccine-induced inhibition of Bordetella pertussis adhesion to airway epithelia (2016) (8)
Molecular Engineering of Ghfp, the Gonococcal Orthologue of Neisseria meningitidis Factor H Binding Protein (2015) (8)
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults (2017) (8)
Antibodies, epicenter of SARS-CoV-2 immunology (2021) (7)
Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269 (2019) (7)
NHBA is processed by kallikrein from human saliva (2018) (6)
Erratum for Baddal et al., Dual RNA-seq of Nontypeable Haemophilus influenzae and Host Cell Transcriptomes Reveals Novel Insights into Host-Pathogen Cross Talk (2016) (6)
Potential impact of the 4CMenB vaccine on oropharyngeal carriage of Neisseria meningitidis. (2017) (6)
The trillion dollar vaccine gap (2022) (6)
Novel molecular biology approaches to acellular vaccines. (1996) (6)
Towards a vaccine against Escherichia coli-associated urinary tract infections. (2010) (6)
Genome Mining and Reverse Vaccinology (2006) (6)
Vaccines 2020: The era of the digital vaccine is here (2021) (5)
The Secretome landscape of Escherichia coli O157:H7: Deciphering the cell-surface, outer membrane vesicle and extracellular subproteomes. (2020) (5)
Characterisation of diverse sub-variants of the meningococcal factor H binding protein ( fHbp ) for their ability to bind fH , mediate serum resistance and induce bactericidal antibodies (2013) (5)
High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007–2011: Concordant predictions between MATS and genetic MATS (2021) (5)
Neisseria gonorrhoeae PIII has a role on NG1873 outer membrane localization and is involved in bacterial adhesion to human cervical and urethral epithelial cells (2013) (5)
The meningococcal vaccine antigen GNA2091 is an analogue of YraP and plays key roles in outer membrane stability and virulence (2019) (5)
4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp (2020) (4)
Genetic detoxification of bacterial toxins. (2003) (4)
Investigation on the Effect of Immune Selection on Resistance to Bactericidal Antibodies to Group B Meningococci In Vitro (2009) (4)
Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy (2021) (4)
Optimized fluorescent labeling to identify memory B cells specific for Neisseria meningitidis serogroup B vaccine antigens ex vivo (2013) (4)
Toxins as Vaccines and Adjuvants (2003) (4)
NMR resonance assignments of NarE, a putative ADP-ribosylating toxin from Neisseria meningitidis (2010) (4)
Genetic detoxification of bacterial toxins. (1996) (4)
Reverse Vaccinology: Revolutionizing the Approach to Vaccine Design (2006) (4)
DNA sequence of a pseudogene for human C-reactive protein. (1987) (3)
Effects of the insertion of a nonapeptide from murine IL-1β on the immunogenicity of carrier proteins delivered by live attenuated Salmonella (1998) (3)
Further analysis of the sequence of the S1 subunit of pertussis toxin (1991) (3)
Identification of lipid A deacylase as a novel, highly conserved and protective antigen against enterohemorrhagic Escherichia coli (2019) (3)
Development and Characterisation of a Four-Plex Assay to Measure Streptococcus pyogenes Antigen-Specific IgG in Human Sera (2022) (3)
Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland (2020) (3)
Intimin-Speciﬁc Immune Responses Prevent Bacterial Colonization by the Attaching-Effacing Pathogen Citrobacter rodentium (2001) (3)
In vivo characterization of the immune response towards the pathogenic Escherichia coli antigen SslE and modulation of the intestinal microbiota (2016) (3)
Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France (2021) (3)
Synergistic activity of antibodies in the multicomponent 4CMenB vaccine (2022) (3)
Whole-Genome Sequences of Nonencapsulated Haemophilus influenzae Strains Isolated in Italy (2015) (2)
Protective Efﬁcacy Induced by Recombinant Clostridium difﬁcile Toxin Fragments (2013) (2)
Spotlight on... Mariagrazia Pizza. (2017) (2)
Toxin-Based Vaccines (Diphtheria, Tetanus, Pertussis) (1999) (2)
Interplay between enterohaemorrhagic Escherichia coli and nitric oxide during the infectious process (2020) (2)
Meningococcal diseases: From genomes to vaccines (2006) (2)
Development of vaccines at the time of COVID-19 (2020) (2)
Four-component Meningococcal Serogroup B Vaccine Induces Antibodies With Bactericidal Activity Against Diverse Outbreak Strains in Adolescents. (2020) (2)
Innovative vaccine approaches—a Keystone Symposia report (2022) (2)
1H, 13C and 15N assignment of the C-terminal domain of GNA2132 from Neisseria meningitidis (2010) (2)
The Neisseria meningitidis ADP-Ribosyltransferase NarE Enters Human Epithelial Cells and Disrupts Epithelial Monolayer Integrity (2015) (2)
Engineering bacterial toxin for the development of new vaccine against pertussis. (1988) (1)
Development of the new acellular recombinant pertussis vaccine. (1994) (1)
METRONIDAZOLE RESISTANCE IN HELICOBACTER PYLORI. AUTHORS' REPLY (1999) (1)
Metronidazole resistance in Helicobacter pylori. (1999) (1)
Neisseria meningitidis population is structured in phylogenetic clades , associated with restriction-modification systems that modulate the effect of homologous recombination (2010) (1)
Faculty Opinions recommendation of Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. (2019) (1)
Faculty Opinions recommendation of Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. (2021) (1)
1H, 13C and 15N assignment of the GNA1946 outer membrane lipoprotein from Neisseria meningitidis (2010) (1)
Reverse vaccinology: From genome to vaccine (2002) (1)
Design of new vaccines in the genomic and post-genomic era (2012) (1)
Development of a vaccine against serogroup B has been the main scientific challenge. Preface. (2012) (1)
Neisseria gonorrhoeae PIII has a role on NG1873 outer membrane localization and is involved in bacterial adhesion to human cervical and urethral epithelial cells (2013) (1)
Subunit S 1 of pertussis toxin : Mapping of the regions essential for ADP-ribosyltransferase activity ( erts toxin / ADP-rlbosylatin / subunlt Sl / site-directed mutagenesis ) (1)
Safety and immunogenicity in animals of subunit influenza vaccine given intranasally with mutants of Escherichia coli heat-labile enterotoxin (LT) (2004) (1)
Genetic approaches to a vaccine for pertussis. (1991) (1)
Identification of non-LPS bacterial ligands for the class A macrophage scavenger receptor on Neisseria meningitidis using a novel assay (2005) (0)
Neisseria meningitidis serogroups compositions b and c-antigenic and containing an additional antigen (2000) (0)
Structural characterization of a cross-protective natural chimera of factor H binding protein from meningococcal serogroup B strain NL096 (2022) (0)
Editorial overview: Vaccines (2022) (0)
Mutated forms of the meningococcal-adp-ribosylating toxins (2003) (0)
Genomic neisseriasekvenser and progress ways of use thereof (2000) (0)
Engineering bacterial toxins for the development of a new vaccine against whooping cough. (1989) (0)
The structure of a N. meningitides protein targeted for vaccine development (2011) (0)
TROMBASTENIA DE GLANZMANN: RELATO DE CASO (2020) (0)
Solution NMR structure of the apoform of NarE (NMB1343) (2010) (0)
Enterotoxin-Based Mucosal Adjuvants Lymphocyte Responses Induced by MHC Class I-Restricted Cytotoxic (1999) (0)
A NOVEL NAD:ARGININE:ADP-RIBOSYLTRANSFERASE FROM NEISSERIA MENINGITIDIS (2001) (0)
Faculty Opinions recommendation of Adaptive evolution of virulence and persistence in carbapenem-resistant Klebsiella pneumoniae. (2020) (0)
Subject Index Vol. 108, 1995 (1995) (0)
Immunogenic, non-toxic mutant of the toxin LT from E. coli a (1997) (0)
coli Escherichia Enterotoxin of Enterotoxigenic Factor Antigen I and Mutant Heat-Labile Strain CVD 1204 Expressing Colonization 2 a Vaccine Shigella flexneri Attenuated (2000) (0)
Development and Characterization of a Luminescence-Based High-Throughput Serum Bactericidal Assay (L-SBA) to Assess Bactericidal Activity of Human Sera against Nontyphoidal Salmonella (2022) (0)
proteins hybrid expression of neisseria (2001) (0)
Faculty Opinions recommendation of Intracellular replication of Streptococcus pneumoniae inside splenic macrophages serves as a reservoir for septicaemia. (2018) (0)
Toxin lt e-a. coli mutant detoxified immunogenic. (1997) (0)
Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes (2018) (0)
Adjuvanticity of a mutant of heat-labile enterotoxin of E. coli for the induction of measles specific CTL responses after intranasal coimmunization with a synthetic peptide (1997) (0)
Neisseria meningitidis protein (1999) (0)
Uropathogenic Escherichia coli immunogens (2006) (0)
Exploring the Role of GMMA Components in the Immunogenicity of a 4-Valent Vaccine against Shigella (2023) (0)
LINFOHISTIOCITOSE HEMOFAGOCÍTICA ASSOCIADA À SÍNDROME DE CHEDIAK-HIGASHI (2021) (0)
An abundance of bacterial ADP-ribosyltransferases – implications for the origin of exotoxins and their human homologues (2001) (0)
MOLECULAR CHARACTERISATION OF A NOVEL ADP-RIBOSYLATING PUTATIVE TOXIN OF NEISSERIA MENINGITIDIS (2002) (0)
ADP-ribosilant bacterial toxins (2002) (0)
Crystal structure reveals vaccine elicited bactericidal human antibody targeting a conserved epitope on meningococcal fHbp (2018) (0)
13 Bacterial Toxins (2004) (0)
Compositions combinations Neisseria (2000) (0)
Hipocalcemia severa o sintomática secundaria a hipoparatiroidismo posoperatorio en cirugía de tiroides: experiencia en un hospital universitario de Medellín, Colombia (2020) (0)
Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis (2017) (0)
Antigenic peptides of Neisseria (2000) (0)
Pertussis toxin mutants, the same producing Bordetella strains and their use as a vaccine against pertussis. (1990) (0)
Faculty Opinions recommendation of A novel therapeutic antibody screening method using bacterial high-content imaging reveals functional antibody binding phenotypes of Escherichia coli ST131. (2020) (0)
Immunization against serogroup meningococcus and proteins using (2005) (0)
Attenuated Shigella ﬂexneri 2a Vaccine Strain CVD 1204 Expressing Colonization Factor Antigen I and Mutant Heat-Labile Enterotoxin of Enterotoxigenic Escherichia coli (2000) (0)
PROTEIN CONFORMATION AFFECTS THE EFFICACY OF PERTUSSIS VACCINES (1991) (0)
Faculty Opinions recommendation of A bacterial effector mimics a host HSP90 client to undermine immunity. (2019) (0)
Improve the bactericidal activity of neisseria antigens containing oligonucleotides with cg (2000) (0)
Compositions immunogenes comportant des antigenes gonococciques multiples (2004) (0)
OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans (2023) (0)
Enzyme Activity Effects of the Nontoxic AB Complex and the Toxin : Distinct Pro-and Anti-Inflammatory Heat-Labile Escherichia coli Responses by Modulation of Innate and Acquired Immune Rappuoli (2000) (0)
Contents, Vol. 108, 1995 (1995) (0)
OMV vaccine supplemented against meningococcus (2001) (0)
Faculty Opinions recommendation of Deep-sea microbes as tools to refine the rules of innate immune pattern recognition. (2021) (0)
Membrane vesicles (omv) with improved properties (2003) (0)
Agonists Able to Activate APCs Bacterial Polysaccharides Generates TLR 2 Introduction of Zwitterionic Motifs into (2007) (0)
Detoxified immunogenic mutant cholera toxins. (1996) (0)
Immunogenic, nontoxic cholera toxin mutant (1996) (0)
Neisserial antigen peptides (2000) (0)
Save the microbes to save the planet. A call to action of the International Union of the Microbiological Societies (IUMS) (2023) (0)
An immunogenic detoxified mutant E. coli LT-A toxin (1997) (0)
Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect (2021) (0)
IDENTIFICATION OF A MECHANISM FOR ENZYMATIC REGULATION IN NARE (2011) (0)
Multiple variants of meningococcal NMB 1870 protein (2003) (0)
Years Isolated from Italian Students Aged 14 to 22 Neisseria meningitidis Carrier Strains Molecular and Serological Diversity of (2014) (0)
Neisseria genomic sequences and methods of use. (2000) (0)
Vaccines for a sustainable planet (2023) (0)
Faculty Opinions recommendation of A proof of concept for structure-based vaccine design targeting RSV in humans. (2019) (0)
IDENTIFICATION OF THE NARE AUTO-ADP-RIBOSYLATION SITE (2010) (0)
Outer Membrane Vesicles (OMV)-based and Proteomics-driven Antigen Selection Identifies Novel Factors Contributing to Bordetella pertussis Adhesion to Epithelial Cells*□S (2018) (0)
Analytical Control Strategy of Bacterial Subunit Vaccines (2015) (0)
Improved vesicles of the outer membrane of the bacteria (2003) (0)
Rational Design of Vaccine Molecules to Prevent Pertussis (1995) (0)
Sepsis associated proteins and nucleic acids of meningitis / Escherichia coli (2006) (0)
BIOCHEMICAL CHARACTERIZATION OF AUTO-ADP-RIBOSYLATED NARE (2011) (0)
New pertussis toxin variant, bordetella bacterial strain capable of producing such variant and its use in development of pertussis vaccine (1996) (0)
Meningococcal Vaccines: A Technological Revolution (2021) (0)
Toxins and toxoids as mucosal immunogens and adjuvants (1996) (0)
The structure of fragment B of FdeC (Factor Adherece E. coli), a novel broadly conserved E. coli adhesin, with structural homology to invasin and intimin (2012) (0)
Vaccinology – Editorial (2020) (0)
Neisseriale antigenic peptides. (2000) (0)
Bacterial outer membrane vesicles improved (2003) (0)
Mucosal vaccines DTPA. (2000) (0)
A life passion for vaccines (2011) (0)
Mucosal immunization with antigens from HIV and opportunistic pathogens using new generation mucosal adjuvants (contribution n.50/B/C) (1999) (0)
Antibodies, epicenter of SARS-CoV-2 immunology (2021) (0)
Vesicles improved bacterial outer membranes. (2003) (0)
Solution structure of the antigenic domain of GNA1870 of Neisseria meningitidis (2006) (0)
Part L - Genome-Based Approach for a Vaccine against Neisseria meningitidis (2003) (0)
Neisseria meningitidis antigenic and assortments (1999) (0)
DISEASE STATES AND VACCINES: SELECTED CASES (2003) (0)
Compositions meningococciques antigeniques a adjuvants (2002) (0)
The emerging problem of AntiMicrobial Resistance and the role of vaccines (2020) (0)
Neisseria antigens and preparations (1999) (0)
Novel Vaccine Candidate of Neisseria meningitidis (2002) (0)
A novel high-throughput assay to quantify the vaccine-induced inhibition of Bordetella pertussis adhesion to airway epithelia (2016) (0)
Development of a serological assay to predict antibody bactericidal activity against non-typeable Haemophilus influenzae (2015) (0)
Animal models in vaccinology: state of the art and future perspectives for an animal-free approach. (2021) (0)
proteins neisseria-heterologous expression of (2001) (0)
AN IRON-SULFUR CLUSTER IN NARE MODULATES ITS ENZYMATIC ACTIVITIES (2009) (0)
Faculty Opinions recommendation of Bifunctional Immunity Proteins Protect Bacteria against FtsZ-Targeting ADP-Ribosylating Toxins. (2018) (0)
Corrigendum: Vaccines Against Antimicrobial Resistance (2020) (0)
K1 Escherichia coli form foci in the brain at 24h post infection (2022) (0)
Membrane vesicles (OMV) vaccine, the n. Meningitidis serogroup B membrane proteins containing (2001) (0)
7. Two-Dose 4CMenB Vaccination in Adolescents Elicits a Bactericidal Activity against 15 Outbreak-Representative Meningococcal Strains (2020) (0)
Addressing the frustrations of finding new effective antibacterials to combat drug resistant bacteria. (2008) (0)
Compositions comprising Neisseria antigens from serogroups miningitidis byc well as other antigen. (2000) (0)
of heat-labile enterotoxin. derivatives and protease sensitivity of nontoxic Mutations in the A subunit affect yield, stability, (2013) (0)
02. Beyond B Antigen Coverage: The Potential of the 4CMenB Vaccine for Cross-protection Against Pathogenic Neisseria Infections (2021) (0)
THE ADP-RIBOSYLTRANSFERASE FROM NEISSERIA MENINGITIDIS DISPLAYS AUTO-ADP-RIBOSYLATION ACTIVITY (2002) (0)
Immunoreactive polypeptide and its production (1988) (0)
Further Analysis oftheSequence oftheSiSubunit of Pertussis Toxin (1991) (0)
Avances recientes en la prevención de la enfermedad meningocócica B: evidencia real de la vacunación con 4CMenB (2021) (0)
ANTIGENE DE NEISSERIA A 85kDa (2000) (0)
Genomics and Proteomics in Vaccine Design (2003) (0)
Gonococcusproteiner and nucleic acids (2002) (0)
heterologous expression of proteins of Neisseria (2001) (0)
protenia multiple variants of NMB 1870 meningococcus (2003) (0)
Hybrid proteins expression Neisserscher (2001) (0)

This paper list is powered by the following services:

Other Resources About Mariagrazia Pizza

en.wikipedia.org

What Schools Are Affiliated With Mariagrazia Pizza?

Mariagrazia Pizza is affiliated with the following schools:

Mariagrazia Pizza's Academic­Influence.com Rankings